Remote-controlled robot called ARES (Auris Robotic Endoscopy System) has now officially entered the international market of medical equipment. This device was released by Auris Surgical, which doesn’t enjoy wide popularity not only all over the world, but in the USA as well. However, it should be noted that this project is being run and developed under the direction of Intuitive Surgical, a company that is engaged in development and production of da Vinci Robotic Surgical System, which has already became popular all over the world.
As for the company that offers this endoscopic equipment, the price of which is still unknown, the Auris Surgical medical community has been known as a company engaged in the manufacture of microsurgical systems for the cataract treatment. It has several serious invention patents that are related exactly to this field of surgery. These days the company has declared its ambitions to expand the area of their own interests and create robotic technology for diagnosis and treatment of other organs and systems’ diseases.
After careful review of patent applications, which had already been sent by Auris, we can conclude that the company will be primarily working on the development of endoluminal surgery. It’s worth recalling that this branch of medicine is engaged in performing surgical operations, using flexible instruments that are introduced through the natural holes. By means of such apparatus, it’s possible to successfully treat diseases of respiratory system and digestive tract.
This robotic endoscopic equipment, the price of which, as it has been said, is still unknown, has many advantages over conventional surgical devices. First of all, while working under X-ray control, not the surgeon, but the robot is exposed to the rays, which fully safeguards operating team from ionizing radiation. Besides that, under the conditions of endoluminal intervention, when the access is being performed through a small incision, the endoscope manipulation requires a complex, at times, acrobatic technique that is greatly simplified thanks to the robotic system.
The certificate, which the ARES manufacturer has obtained from the FDA, is valid only for the treatment and diagnosis of lung diseases. The study, which was submitted to the controlled monitoring, consisted of a pilot survey of 15 patients. The robot was able to fully explore the respiratory tree without any side effects of all patients without exception. Besides, eight out of nine patients, who had lung cancer, managed to undergo pathological tissue biopsy. Now the company is working on obtaining a certificate for using the robot in treatment of other organs and systems’ diseases.